Thomas Leblanc, MD
Medical Oncology · Durham, NCNPI 1790997989
Payments from drug & device makers
Across 1,362 payments — averaging $1763.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$567K
- AbbVie$333K
- Jazz Pharmaceuticals Inc.$255K
- GSK$224K
- Bristol Myers Squibb$195K
- Incyte Corporation$160K
- plus $667K from 26 others
Across 56 payments — averaging $2762.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$108K
- Servier Bioinnovation$17K
- Pfizer$12K
- Astellas Pharma Global Development$8K
- Amgen$5K
- Servier Pharmaceuticals LLC$4K
- plus $455 from 1 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 404 | $567,482 |
| AbbVie | 245 | $332,657 |
| Jazz Pharmaceuticals Inc. | 11 | $255,167 |
| GSK | 9 | $224,409 |
| Bristol Myers Squibb | 119 | $194,954 |
| Incyte Corporation | 151 | $159,517 |
| AstraZeneca | 22 | $145,404 |
| Servier Pharmaceuticals LLC | 99 | $122,758 |
| Agios Pharmaceuticals, Inc. | 69 | $75,804 |
| Rigel Pharmaceuticals, Inc. | 33 | $62,921 |
| Stemline Therapeutics Inc. | 56 | $61,092 |
| Astellas Pharma US Inc | 22 | $35,986 |
| Pfizer | 20 | $25,806 |
| Daiichi Sankyo Inc. | 18 | $23,128 |
| Geron Corporation | 15 | $22,566 |
| Novartis | 13 | $16,397 |
| Genentech USA, Inc. | 8 | $15,444 |
| Syndax Pharmaceuticals, Inc. | 12 | $12,444 |
| Eli Lilly | 3 | $11,700 |
| Astellas Pharma Global Development | 5 | $9,655 |
| Autolus Inc | 1 | $6,475 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $3,900 |
| Gilead | 1 | $3,840 |
| Taiho Oncology, Inc. | 2 | $3,242 |
| Astrazeneca UK Limited | 5 | $2,238 |
| Seagen Inc. | 3 | $1,740 |
| Amgen | 7 | $1,518 |
| Janssen Scientific Affairs, LLC | 1 | $1,263 |
| Acceleron Pharma, Inc. | 1 | $1,000 |
| Genentech, Inc. | 1 | $550 |
| Beigene, Ltd. | 1 | $450 |
| Adaptive Biotechnologies Corporation | 1 | $122 |
How this compares
$2,401,629 in reported general payments places this provider in the 90th percentile of 170 medical oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Durham
- John StricklerDurham$23.5M
- Andrew ArmstrongDurham$8.6M
- Jeffrey ClarkeDurham$7.7M
- Neal ReadyDurham$6.7M
- Niharika MettuDurham$3.7M
- Michael HarrisonDurham$3.1M
- Brent HanksDurham$1.5M
- Jingquan JiaDurham$502K
- Sundhar RamalingamDurham$282K
- Jeffrey ShevachDurham$246K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.